SlideShare a Scribd company logo
P
REFORMULATION OF
P
ARENTRAL P
RODUCT

BY,

11/03/13

Joan Vijetha.R
M.Pharm(pharmacutices)

1
CONTENT
 Introduction.
 Definition.
 Pre-formulation






11/03/13

studies

Bulk characterisation.
Solubility analysis.
Stability analysis.
Spectroscopy.
Microscopy.
Chromatography .
2
INTRODUCTION
 Pre-formulation

testing is the first step in the
rational development of dosage forms.
 Pre-formulation study is done mainly to
develop efficient dosage form.
 Gives information for design of dosage form.
 Used to identify molecular structure,
formula, molecular weight, etc.
 Therapeutic identification.
11/03/13

3
Definition
refers injectable route of
administration. It derived from Greek words
Para (Outside) and enter on (Intestine). So it
is a route of administration other than the
oral route.

 Parenteral

is done prior to
development of dosage form, it is essential
that certain fundamental physical and
chemical properties of the drug molecule and
other derivative properties of the drug is
11/03/13
4
determined.
 Per-formulation
Bulk characterisation
Bulk properties of the solid form such as
Crystallinity,
Polymorphism,
Particle size,
Powder flow property,
and
Surface characteristics are likely to change
during process development.

11/03/13

5
Crystallinity


Crystal habit and internal structure of a drug
can affect bulk and physicochemical
properties, which range form flow ability to
chemical stability.



The crystal habit describes the outer
appearance of crystals( plate, equate, needle,
bladed, etc.) and internal structure
arrangement.

11/03/13

6
Polymorphism
polymorphism is the ability of the
compound to crystallize as more than one
distinct crystalline species with different
internal structure.
 Formation of different polymorphs depends
on solvents, temperature, pressure, rate of
cooling, etc.
 Polymorphic transitions can also occur
during milling, granulating, drying and
compressing operations
 Different polymorphs vary in physical
properties such as dissolution, solid-state
11/03/13
7
stability, compatibility, etc.

Particle size







Study of particle size give an information about
solubility, dissolution rate, absorption, etc.
Fine particle characterization very important
property and here smallest particle should be tested
to facilitate homogeneous sample preparation.
Counter current Technique-To check particle size
and particle volume
BET (Brunauer, Emmet, Teller) Nitrogen
Adsorption Apparatus -Measurement of surface area
SEM( Scanning Electron Microscopy)- to check
surface morphology .

11/03/13

8
Powder flow property


The flow properties of a powder will
determine the nature and quantity of
excipients needed to prepare a
compressed or a powder dosage form.



This refers mainly to factors such
as the ability to process the powder
through machines.

11/03/13

9
HYGROSCOPICITY
 The

tendency of a solid to take up
water from the atmosphere, as it is
subjected to a controlled RH program
under isothermal condition i.e.
hygroscopicity.

 Classified

based on the amount of rate
of water uptake when a solid is exposed
to controlled RH value at a specified
11/03/13
10
temperature.
SOLUBILITY ANALYSIS
 Aqueous

Solubility
 Drug Pka / Ionization At Physiological
Ph
 Partition Coefficient
 Thermal effect

11/03/13

11
Aqueous Solubility


Solubilisation is increased by addition of cosolvent



E.g.-

propylene

molecules

by

glycol

disrupting

solubilize
the

drug

hydrophobic

interactions of water.
More non polar the solute

11/03/13

greater is the solubilisation

12
Drug pKa / Ionization at
physiological pH


pKa is the dissociation constant of a
drug.



The non ionized substances is lipid
soluble thus dissolve in lipid material
of the membrane and transported by
passive diffusion.

11/03/13


Where as, the ionized substances is 13


The percentage of ionization can be calculated as …



For Acidic compounds:

% ionized = 100/ 1+ antilog (pKa – pH)


For Basic compounds:

% ionized = 100/ 1+ antilog (pH – pKa)


11/03/13

Degree of ionization depends up on the pH.
for acidic drugs pKa ranges from 3-7.5.
for basic drugs pKa ranges from 7-11.
14
PARTITION COEFFICIENT
 Partition

coefficient influence permeation
of a drug across biological membrane.

 Partition

coefficient is a ratio of
equilibrium concentration of drug in oil
phase to equilibrium concentration of drug
in aqueous phase .
K=Co/Cw

where, C o -organic phase concentration
C w -aqueous phase concentration
11/03/13

15
THERMAL/HEAT
EFFECTS
Drugs which are unstable to heat requires refrigerate
storage or lyophilisation (these products must be used
within short periods)
 If it is endothermic ---> ∆H is +ve
increase in temp ---> increase in drug solubility
 If it is exothermic ---> ∆H is – ve
increase in temp ---> decrease in drug solubility
 For determining ∆H
ln S= - ∆H /RT + C
S=molar solubility at temperature,
T=temperature in Kelvin,
R= gas constant


11/03/13

16
Stability analysis
 Stability

in toxicology formulation.
 Solution stability.
 Solid state stability.

11/03/13

17
Stability in toxicology
formulation
 Toxicology

studies typically commence
early in development, it is often
advisable to evaluate samples of the
toxicology preparation for stability and
potential homogeneity problems.

11/03/13

18
Solution stability
 The

primary objective of this phase of
pre-formulation research is
identification of condition necessary to
form a stable solution.

 This

study include-effect of pH, ionic
strength, light, temperature and oxygen

11/03/13

19
Solid state stability
• Solid phase stability depends on several
factors like temperature, pH, humidity,
hydrolysis, oxidation, etc
• For a new drug compound
Weighed sample are place in open screw cap
vials and are exposed directly to light, temp,
humidity for 12weeks.

11/03/13

20
STORAGE
CONDITION

4WEEKS

8WEEKS

12WEEKS

5o C-REFRIGERATOR
22OC- ROOM TEMP
37OC-AMBIENT
HUMIDITY
50OC-AMBIENT
HUMIDITY
70OC-AMBIENT
HUMIDITY
90OC-AMBIENT
HUMIDITY
37OC/75%R.H
11/03/13

21
Hydrolysis
 Important

factor in drug stability.
 Hydrolytic reaction involves
nucleophilic attack.
 The condition catalysis the brake down
as follows
•
•
•

11/03/13

Presence of OH.
Presence of divalent metal ion.
Presence of light and heat.
22
Oxidation and
Reduction
 Oxidation

is controlled by
environment(i.e.) light, oxygen &
oxidizing agent.
 Reduction is based on redox reaction
where there is mutual change in
electrons.

11/03/13

23
Spectroscopy
UV and Visible Spectrophotometry: When
organic molecules in solution, or as liquid, are
exposed to light in the visible and ultraviolet
light regions of spectrum, they absorb light of
particular wavelengths depending on the type
of electronic transition that is associated with
the absorption.
 IR Spectrophotometer: The study of the
interaction of electromagnetic radiation with
vibrational and rotational resonances within a
molecular structure is termed as IR
Spectroscopy.
 X-Ray Diffraction: When a beam of non
homogenous x-rays is allowed to pass through 24
11/03/13

Microscopy
 In

this technique substances are examined
under the microscope.

It gives information about shape, thickness,
particle size, etc. of drug molecules.

By this method we can study crystal
morphology, difference between polymorphic
character of molecule.

11/03/13

25
Chromatography
In the pre-formulation studies,
chromatographic techniques such as TLC,
HPLC,GC carrying a major role.
 Analytical data from TLC may be required to
precisely determine the kinetics of
decomposition.
 HPLC and GC are useful for solubility
measurements


11/03/13

26
SUMMARY
 Preformulation

studies on a new drug
molecule provide useful information
for subsequent formulation of a
Physicochemically stable and
Biopharmaceutically suitable dosage
form.
 Thorough Preformulation work is the
foundation of developing efficacious
and economical formulations.
11/03/13

27
REFERENCE







Remington, The Science And Practice Of Pharmacy,
20th Edition,pg.940-42.
Leon Lachman, Herbert Al, Joseph Lk., The
Theory And Practice Of Industrial Pharmacy, 3rd
Ed.Pg. 171- 196.
Bhatt Bhavik R, A SEMINAR ON
PREFORMULATION
STUDIES:PHYSICOCHEMICAL
CHARACTERIZATION OF NEW DRUG
MOLECULES.
Manjul Pratap Singh & Anita Singh, Parenteral
Products.

11/03/13

28
THANK You...

THANK
You...

THANK
THANK You...

11/03/13

29

More Related Content

PPT
Preformulation
PPTX
Tablet coating - industrial pharmacy
PDF
LIQUID ORALS INDUSTRIAL PHARMACY
PPTX
Tablet types and Excipients
PPTX
Quality Control of Aerosols
PPTX
Preformulation Studies
PPT
capsules.ppt
PPTX
Pellets- Industrial pharmacy
Preformulation
Tablet coating - industrial pharmacy
LIQUID ORALS INDUSTRIAL PHARMACY
Tablet types and Excipients
Quality Control of Aerosols
Preformulation Studies
capsules.ppt
Pellets- Industrial pharmacy

What's hot (20)

PPTX
Parenteral Products
PPTX
Parameters in Preformulation Studies
PPTX
Tablet defects
PPTX
Preformulation Studies (Chemical Properties) Industrial Pharmacy 1st
PPTX
Preformulation studies(unit 1)
PPTX
Drug technical advisory board (dtab)
PPTX
Parentrals
PPT
Propellants in-pharmaceutical-aerosols
PPTX
Liquid orals for pharm.D
PPTX
Preformulation (chemical properties)
PPTX
Quality control & evaluation of aerosol
PPTX
Bcs classification by sneha gaurkar
PDF
Formulation and preparation of cold cream and vanishing cream
PPTX
Tablet coating.pptx
PPTX
Drugs & Cosmetics Act 1940 part III
PPTX
Parenteral products
PPTX
Formulation and evaluation of aerosals
PPTX
Preformulation studies
PPTX
Tablet tooling
Parenteral Products
Parameters in Preformulation Studies
Tablet defects
Preformulation Studies (Chemical Properties) Industrial Pharmacy 1st
Preformulation studies(unit 1)
Drug technical advisory board (dtab)
Parentrals
Propellants in-pharmaceutical-aerosols
Liquid orals for pharm.D
Preformulation (chemical properties)
Quality control & evaluation of aerosol
Bcs classification by sneha gaurkar
Formulation and preparation of cold cream and vanishing cream
Tablet coating.pptx
Drugs & Cosmetics Act 1940 part III
Parenteral products
Formulation and evaluation of aerosals
Preformulation studies
Tablet tooling
Ad

Viewers also liked (20)

PPT
1. preformulation
PDF
Preformulation
PPTX
parenterals
PPTX
parenterals....formulation & evaluation
PPT
Preformulation
PPT
Parentral route and formulation
PPT
Parenteral drug delivery
PPTX
Parenteral production
PPSX
Parenteral preparation, equipments and layout
PPT
Evaluation of transdermal drug delivery system
DOCX
Construction of calibration curve for uv-spectroscopic analysis of Paracetamol.
PPT
Preformulation
PPTX
Evaluation of parenterals
PPT
Telephone Etiquette
PPT
Penetration enhancers Used in transdermal drug delivry
PPTX
Parenteral production and aseptic area
PPTX
Quality control tests for parenterals ppt
PPTX
Parenterals
PPT
Quality Assurance Vs Quality Control
PPTX
Quality control and quality assurance
1. preformulation
Preformulation
parenterals
parenterals....formulation & evaluation
Preformulation
Parentral route and formulation
Parenteral drug delivery
Parenteral production
Parenteral preparation, equipments and layout
Evaluation of transdermal drug delivery system
Construction of calibration curve for uv-spectroscopic analysis of Paracetamol.
Preformulation
Evaluation of parenterals
Telephone Etiquette
Penetration enhancers Used in transdermal drug delivry
Parenteral production and aseptic area
Quality control tests for parenterals ppt
Parenterals
Quality Assurance Vs Quality Control
Quality control and quality assurance
Ad

Similar to Pre formulation (20)

PPTX
preformulation
PPTX
Preformulation
PPTX
Umesh bhandari
PPTX
Preformulation concept
PPTX
PREFORMULATION STUDIES OF DRUGS PRESENTED BY MANSI SANGRI
PPT
Evaluation methods for drug excipients and container interaction
PPT
Physiochemical factors influencing formulaon
PPTX
PREFORMULATION STUDY IN DESIGNING OF TABLET DOSAGES FORM.pptx
PPTX
Preformulation.pptx
PPTX
Bppk ppt
PDF
Industrial Pharmacy Notes for M.Pharmacy
PPTX
PARTITION COEFFICIENT
DOCX
Drug excipient interaction assignment
PPTX
Madhavi mutha
PPTX
Parenteral drug delivery
PPTX
pharma DRUG – EXCIPIENT INTERACTIONS.pptx
PPTX
Solubility enhancement technique of BCS Class II drug by Solvent Evaporatiom
PPTX
preformulation concepts, drug excipient interactions different methods slide...
PPTX
1.preformulation concept in Modern pharmaceutics.pptx
preformulation
Preformulation
Umesh bhandari
Preformulation concept
PREFORMULATION STUDIES OF DRUGS PRESENTED BY MANSI SANGRI
Evaluation methods for drug excipients and container interaction
Physiochemical factors influencing formulaon
PREFORMULATION STUDY IN DESIGNING OF TABLET DOSAGES FORM.pptx
Preformulation.pptx
Bppk ppt
Industrial Pharmacy Notes for M.Pharmacy
PARTITION COEFFICIENT
Drug excipient interaction assignment
Madhavi mutha
Parenteral drug delivery
pharma DRUG – EXCIPIENT INTERACTIONS.pptx
Solubility enhancement technique of BCS Class II drug by Solvent Evaporatiom
preformulation concepts, drug excipient interactions different methods slide...
1.preformulation concept in Modern pharmaceutics.pptx

More from joan vijetha (8)

PDF
What are the different type of validation
PDF
Organization and personnel (QUALITY ASSURANCE).pdf
PDF
suspension (stability related problem).pdf
PPTX
Hot spots
PPTX
Innovation
PPTX
schedule M & Y
PPT
skin care cosmetics
PPTX
Application of ir
What are the different type of validation
Organization and personnel (QUALITY ASSURANCE).pdf
suspension (stability related problem).pdf
Hot spots
Innovation
schedule M & Y
skin care cosmetics
Application of ir

Recently uploaded (20)

PDF
From MVP to Full-Scale Product A Startup’s Software Journey.pdf
PPTX
TLE Review Electricity (Electricity).pptx
PDF
ENT215_Completing-a-large-scale-migration-and-modernization-with-AWS.pdf
PDF
Transform Your ITIL® 4 & ITSM Strategy with AI in 2025.pdf
PDF
A comparative analysis of optical character recognition models for extracting...
PDF
Assigned Numbers - 2025 - Bluetooth® Document
PDF
Profit Center Accounting in SAP S/4HANA, S4F28 Col11
PDF
Unlocking AI with Model Context Protocol (MCP)
PPTX
A Presentation on Touch Screen Technology
PDF
NewMind AI Weekly Chronicles - August'25-Week II
PDF
Microsoft Solutions Partner Drive Digital Transformation with D365.pdf
PPTX
SOPHOS-XG Firewall Administrator PPT.pptx
PDF
Approach and Philosophy of On baking technology
PDF
DASA ADMISSION 2024_FirstRound_FirstRank_LastRank.pdf
PDF
Hindi spoken digit analysis for native and non-native speakers
PPTX
TechTalks-8-2019-Service-Management-ITIL-Refresh-ITIL-4-Framework-Supports-Ou...
PDF
Building Integrated photovoltaic BIPV_UPV.pdf
PDF
7 ChatGPT Prompts to Help You Define Your Ideal Customer Profile.pdf
PDF
Hybrid model detection and classification of lung cancer
PDF
Accuracy of neural networks in brain wave diagnosis of schizophrenia
From MVP to Full-Scale Product A Startup’s Software Journey.pdf
TLE Review Electricity (Electricity).pptx
ENT215_Completing-a-large-scale-migration-and-modernization-with-AWS.pdf
Transform Your ITIL® 4 & ITSM Strategy with AI in 2025.pdf
A comparative analysis of optical character recognition models for extracting...
Assigned Numbers - 2025 - Bluetooth® Document
Profit Center Accounting in SAP S/4HANA, S4F28 Col11
Unlocking AI with Model Context Protocol (MCP)
A Presentation on Touch Screen Technology
NewMind AI Weekly Chronicles - August'25-Week II
Microsoft Solutions Partner Drive Digital Transformation with D365.pdf
SOPHOS-XG Firewall Administrator PPT.pptx
Approach and Philosophy of On baking technology
DASA ADMISSION 2024_FirstRound_FirstRank_LastRank.pdf
Hindi spoken digit analysis for native and non-native speakers
TechTalks-8-2019-Service-Management-ITIL-Refresh-ITIL-4-Framework-Supports-Ou...
Building Integrated photovoltaic BIPV_UPV.pdf
7 ChatGPT Prompts to Help You Define Your Ideal Customer Profile.pdf
Hybrid model detection and classification of lung cancer
Accuracy of neural networks in brain wave diagnosis of schizophrenia

Pre formulation

  • 1. P REFORMULATION OF P ARENTRAL P RODUCT BY, 11/03/13 Joan Vijetha.R M.Pharm(pharmacutices) 1
  • 2. CONTENT  Introduction.  Definition.  Pre-formulation       11/03/13 studies Bulk characterisation. Solubility analysis. Stability analysis. Spectroscopy. Microscopy. Chromatography . 2
  • 3. INTRODUCTION  Pre-formulation testing is the first step in the rational development of dosage forms.  Pre-formulation study is done mainly to develop efficient dosage form.  Gives information for design of dosage form.  Used to identify molecular structure, formula, molecular weight, etc.  Therapeutic identification. 11/03/13 3
  • 4. Definition refers injectable route of administration. It derived from Greek words Para (Outside) and enter on (Intestine). So it is a route of administration other than the oral route.  Parenteral is done prior to development of dosage form, it is essential that certain fundamental physical and chemical properties of the drug molecule and other derivative properties of the drug is 11/03/13 4 determined.  Per-formulation
  • 5. Bulk characterisation Bulk properties of the solid form such as Crystallinity, Polymorphism, Particle size, Powder flow property, and Surface characteristics are likely to change during process development. 11/03/13 5
  • 6. Crystallinity  Crystal habit and internal structure of a drug can affect bulk and physicochemical properties, which range form flow ability to chemical stability.  The crystal habit describes the outer appearance of crystals( plate, equate, needle, bladed, etc.) and internal structure arrangement. 11/03/13 6
  • 7. Polymorphism polymorphism is the ability of the compound to crystallize as more than one distinct crystalline species with different internal structure.  Formation of different polymorphs depends on solvents, temperature, pressure, rate of cooling, etc.  Polymorphic transitions can also occur during milling, granulating, drying and compressing operations  Different polymorphs vary in physical properties such as dissolution, solid-state 11/03/13 7 stability, compatibility, etc. 
  • 8. Particle size      Study of particle size give an information about solubility, dissolution rate, absorption, etc. Fine particle characterization very important property and here smallest particle should be tested to facilitate homogeneous sample preparation. Counter current Technique-To check particle size and particle volume BET (Brunauer, Emmet, Teller) Nitrogen Adsorption Apparatus -Measurement of surface area SEM( Scanning Electron Microscopy)- to check surface morphology . 11/03/13 8
  • 9. Powder flow property  The flow properties of a powder will determine the nature and quantity of excipients needed to prepare a compressed or a powder dosage form.  This refers mainly to factors such as the ability to process the powder through machines. 11/03/13 9
  • 10. HYGROSCOPICITY  The tendency of a solid to take up water from the atmosphere, as it is subjected to a controlled RH program under isothermal condition i.e. hygroscopicity.  Classified based on the amount of rate of water uptake when a solid is exposed to controlled RH value at a specified 11/03/13 10 temperature.
  • 11. SOLUBILITY ANALYSIS  Aqueous Solubility  Drug Pka / Ionization At Physiological Ph  Partition Coefficient  Thermal effect 11/03/13 11
  • 12. Aqueous Solubility  Solubilisation is increased by addition of cosolvent  E.g.- propylene molecules by glycol disrupting solubilize the drug hydrophobic interactions of water. More non polar the solute 11/03/13 greater is the solubilisation 12
  • 13. Drug pKa / Ionization at physiological pH  pKa is the dissociation constant of a drug.  The non ionized substances is lipid soluble thus dissolve in lipid material of the membrane and transported by passive diffusion. 11/03/13  Where as, the ionized substances is 13
  • 14.  The percentage of ionization can be calculated as …  For Acidic compounds: % ionized = 100/ 1+ antilog (pKa – pH)  For Basic compounds: % ionized = 100/ 1+ antilog (pH – pKa)  11/03/13 Degree of ionization depends up on the pH. for acidic drugs pKa ranges from 3-7.5. for basic drugs pKa ranges from 7-11. 14
  • 15. PARTITION COEFFICIENT  Partition coefficient influence permeation of a drug across biological membrane.  Partition coefficient is a ratio of equilibrium concentration of drug in oil phase to equilibrium concentration of drug in aqueous phase . K=Co/Cw where, C o -organic phase concentration C w -aqueous phase concentration 11/03/13 15
  • 16. THERMAL/HEAT EFFECTS Drugs which are unstable to heat requires refrigerate storage or lyophilisation (these products must be used within short periods)  If it is endothermic ---> ∆H is +ve increase in temp ---> increase in drug solubility  If it is exothermic ---> ∆H is – ve increase in temp ---> decrease in drug solubility  For determining ∆H ln S= - ∆H /RT + C S=molar solubility at temperature, T=temperature in Kelvin, R= gas constant  11/03/13 16
  • 17. Stability analysis  Stability in toxicology formulation.  Solution stability.  Solid state stability. 11/03/13 17
  • 18. Stability in toxicology formulation  Toxicology studies typically commence early in development, it is often advisable to evaluate samples of the toxicology preparation for stability and potential homogeneity problems. 11/03/13 18
  • 19. Solution stability  The primary objective of this phase of pre-formulation research is identification of condition necessary to form a stable solution.  This study include-effect of pH, ionic strength, light, temperature and oxygen 11/03/13 19
  • 20. Solid state stability • Solid phase stability depends on several factors like temperature, pH, humidity, hydrolysis, oxidation, etc • For a new drug compound Weighed sample are place in open screw cap vials and are exposed directly to light, temp, humidity for 12weeks. 11/03/13 20
  • 21. STORAGE CONDITION 4WEEKS 8WEEKS 12WEEKS 5o C-REFRIGERATOR 22OC- ROOM TEMP 37OC-AMBIENT HUMIDITY 50OC-AMBIENT HUMIDITY 70OC-AMBIENT HUMIDITY 90OC-AMBIENT HUMIDITY 37OC/75%R.H 11/03/13 21
  • 22. Hydrolysis  Important factor in drug stability.  Hydrolytic reaction involves nucleophilic attack.  The condition catalysis the brake down as follows • • • 11/03/13 Presence of OH. Presence of divalent metal ion. Presence of light and heat. 22
  • 23. Oxidation and Reduction  Oxidation is controlled by environment(i.e.) light, oxygen & oxidizing agent.  Reduction is based on redox reaction where there is mutual change in electrons. 11/03/13 23
  • 24. Spectroscopy UV and Visible Spectrophotometry: When organic molecules in solution, or as liquid, are exposed to light in the visible and ultraviolet light regions of spectrum, they absorb light of particular wavelengths depending on the type of electronic transition that is associated with the absorption.  IR Spectrophotometer: The study of the interaction of electromagnetic radiation with vibrational and rotational resonances within a molecular structure is termed as IR Spectroscopy.  X-Ray Diffraction: When a beam of non homogenous x-rays is allowed to pass through 24 11/03/13 
  • 25. Microscopy  In this technique substances are examined under the microscope.  It gives information about shape, thickness, particle size, etc. of drug molecules.  By this method we can study crystal morphology, difference between polymorphic character of molecule. 11/03/13 25
  • 26. Chromatography In the pre-formulation studies, chromatographic techniques such as TLC, HPLC,GC carrying a major role.  Analytical data from TLC may be required to precisely determine the kinetics of decomposition.  HPLC and GC are useful for solubility measurements  11/03/13 26
  • 27. SUMMARY  Preformulation studies on a new drug molecule provide useful information for subsequent formulation of a Physicochemically stable and Biopharmaceutically suitable dosage form.  Thorough Preformulation work is the foundation of developing efficacious and economical formulations. 11/03/13 27
  • 28. REFERENCE     Remington, The Science And Practice Of Pharmacy, 20th Edition,pg.940-42. Leon Lachman, Herbert Al, Joseph Lk., The Theory And Practice Of Industrial Pharmacy, 3rd Ed.Pg. 171- 196. Bhatt Bhavik R, A SEMINAR ON PREFORMULATION STUDIES:PHYSICOCHEMICAL CHARACTERIZATION OF NEW DRUG MOLECULES. Manjul Pratap Singh & Anita Singh, Parenteral Products. 11/03/13 28